Gilead Sciences, Inc. | Drug Pricing


Signatories are invited to vote in favour of this resolution calling for Gilead Sciences, Inc. to issue a report listing the price increases of the company’s top ten selling branded prescription drugs between 2010 and 2016, including the rationale and criteria used for these price increases, and an assessment of the legislative, regulatory, reputational and financial risks they represent.

This content is for signatories only. If you have a signatory account, please log in to view all collaboration content.